Somaiah, Neeta
Paudyal, Bishnuhari
Winkler, Robert E.
Van Tine, Brian A.
Hirbe, Angela C.
Funding for this research was provided by:
Ascentage Pharma
Article History
Accepted: 30 May 2024
First Online: 2 July 2024
Declarations
:
: This review was supported by Ascentage Pharma Group Corp. Ltd. (Hong Kong). The authors were not compensated for their roles in drafting and reviewing the manuscript, had free and unfettered access to all data (published references), and had full autonomy over all decisions concerning content. Stephen W. Gutkin with Ascentage Pharma Group Inc. provided further substantive input in manuscript research and preparation.
: N.S. reports current clinical trial research funding/grant support through her institution from AstraZeneca, Ascentage, Deciphera, Cogent, Boehringer Ingelheim, IDRX, Ningo Newbay, and Bayer. She reports serving as an Advisory Board consultant (last 2 years) for Aadi Biosciences, Adaptimmune, Bayer, Deciphera, and Boehringer Ingelheim. B.P. and R.W. report being full-time employees of Ascentage Pharma Group Inc. and shareholders in the parent, Ascentage Pharma Group International, B.V.T. reports a research grant from Polaris; royalties of licenses from Accuronix Therapeutics; consulting relationships with Aadi Biosciences, Acuta Capital Partners, LLC, Advenchen Laboratories, Bayer, Boxer Capital LLC, Cytokinetics Inc, Daiichi Sankyo Inc, Deciphera Pharmaceuticals, EcoR1, Kronos Bio, Inc., Putnam, Race Oncology, Salarius Pharmaceuticals, Inc., and Sonata Therapeutics, Inc.; payments or honoraria from Iterion Therapeutics, Inc., and Total Health Conference; support for attending meetings and/or travel from Adaptimmune, Advnchen, Kronos Bio, and Polaris; patents on ALEXT3102 and the use of ME1 as a biomarker; participation on Data Safety Monitoring or Advisory Boards for Aadi Biosciences, Agenus, Apexigen, Inc., Bayer US Medical Affairs Oncology, Boehringer Ingelheim, Curis, Daiichi Sankyo, Epizyme, PTC Therapeutics, and Regeneron Pharmaceuticals; and leadership or fiduciary roles in other board, society, committee, or advocacy group with Polaris (nonpaid safety monitoring board). A.C.H. reports royalties or licenses from Boehringer Ingelheim GmbH and Deutsches Krebsforschungszentrum (licensing/product development agreements); consulting fees from Springworks; payments or honoraria from the American Physician Institute for Advanced Professional Studies and Empartners; support for attending meetings and/or travel from Alexion Pharmaceuticals, Inc.; and participation on Data Safety Monitoring or Advisory Boards from Alexion Pharmaceuticals and AstraZeneca Pharmaceuticals LP.
: Not applicable.
: Not applicable.
: All authors.
: All data originated from published references.
: Not applicable.
: All authors played a role in conceiving the review; acquiring and analyzing data; drafting, reviewing, revising, and approving the manuscript; and the decision to submit it for publication. No datasets were generated or analyzed during the current study.